Our mission is to digitize, decode, and decipher human biology for the prevention, early diagnosis, and treatment of chronic diseases and cancer.
A Signal in the Noise
The proprietary combination of Viome's metatranscriptomic sequencing technology, our systems biology approach, and our AI machine learning platform is revolutionizing the health and wellness industry and transforming the potential for early diagnostics and targeted therapeutics.
Our Science & Unique Approach to Human Health
Evidence-based precision nutrition improves clinical outcomes by analyzing human and microbial molecular data with artificial intelligence.
RNA Analysis
Microbial and human gene expression are redefining how biological activities are viewed in relation to human health.
RNA plays a fundamental role in human biology referring the instructions stored in DNA to make the proteins required in every living cell. Our approach is to use RNA medicines to instruct a patient's own cells to produce proteins that could prevent, treat, or cure disease.
DNA vs RNA
DNA
- Rarely changes
- Similar sequence in every organ & cell
- Explains 5-10% of chronic diseases
RNA
- Dynamic, constantly changing
- Vastly different expression in the body
- Explains 80% of chronic diseases
RNA Analysis
System Biology
Our AI Platform
Metatranscriptomic technology
Insight to Intervention
Our RNA platform for Wellness, Diagnostics, and Therapeutics allows us to translate information into valuable insights and meaningful interventions.
WELLNESS
Our direct-to-consumer service analyzes gene expressions (RNA) in order to provide individuals with health insights and precision nutrition to live a healthier life.
This platform of over 400,000 samples enables us to enhance our understanding of human biology as a system in order to develop predictive biomarkers, precision diagnostics, and precision therapeutics to prevent and intercept chronic diseases.
Clinical improvements in IBS, Diabetes, Depression & Anxiety
DIAGNOSTICS
Our predictive biomarkers provide us with the hypothesis to do clinical research and identify the signatures of chronic disease, cancers and aging.
Successfully developed over 30 predictive models for glycemic response, obesity, diabetes, depression, IBS, and oral & throat cancer, which represent over 50% of chronic diseases.
Breakthrough Device Designation for accelerated review by FDA to detect all stage oral cancer and throat cancer with 95% specificity and 90% plus sensitivity (CancerDetect test)
® Oral and Throat test is not an FDA-approved or cleared test)
THERAPEUTICS
The signatures found through diagnostics allow us to determine the mechanism of actions to develop precision therapeutics in the form of drugs, vaccines and treatments.
Viome can determine drug effectivess, including immunotherapy, which is dependent upon the human microbiome.
Ongoing partnerships with large pharmaceutical companies to develop vaccines for colorectal cancer and autoimmune diseases.
Our Approach to Cancer Diagnostics
Viome is committed to identifying the molecular determinants of cancer by systematically evaluating the host and/or microbial activities involved in disease onset and progression.
Carefully define the disease and non-disease cohorts based on all available clinical meta-data.
Systematically analyze those cohorts to identify a molecular signature, typically consisting of both human and microbial molecular features, that distinguishes the disease cohort from the non-disease cohort.
Validate the discovered molecular signature using an unseen independent cohort that includes clinically adjudicated meta-data.
CancerDetect®
Oral & Throat
Our CancerDetect®- Oral & Throat test was developed over multiple years by Viome Life Sciences, Inc, based on clinical studies for diagnostic development and validation. This test is a non-invasive, at-home test that detects a molecular signature associated with Oral and/or Throat cancers with high accuracy.
Viome's commercially available CancerDetect Oral and Throat cancer test is a laboratory-developed test (LDT). This test was clinically validated with an independent cohort, with a specificity of 95% and a sensitivity of 90% for both Oral Squamous Cell Carcinoma (OSCC) and Oropharyngeal Squamous Cell Carcinoma (OPSCC). The test delivers substantially higher sensitivity and specificity over conventional oral exam
"Early detection of Oral and Throat cancer saves lives. With Viome's simple non-invasive at-home test, you can have peace of mind. And we will continuously improve this test so you can get the best technology available in the market!"
Guru Banavar
Founding CTO & Head of Discovery AI,
Viome Life Sciences
VIOME STUDY INITIATIVES
Cancer Research
In addition to head and neck cancers, Viome has an extensive ongoing clinical study pipeline in gastrointestinal cancers including colorectal cancer, pancreatic, ovarian, cervical, and biliary cancers. We currently have cancer research trials that use saliva, blood, stool, and tumor biopsies to understand the onset and progression of cancer. By identifying the biomarkers that lead to the development of cancers, Viome can optimize early detection and identify the right therapeutic targets.
VIOME STUDY INITIATIVES
Cancer Research
In addition to head and neck cancers, Viome has an extensive ongoing clinical study pipeline in gastrointestinal cancers including colorectal cancer, pancreatic, ovarian, cervical, and biliary cancers. We currently have cancer research trials that use saliva, blood, stool, and tumor biopsies to understand the onset and progression of cancer. By identifying the biomarkers that lead to the development of cancers, Viome can optimize early detection and identify the right therapeutic targets.
Publications
The salivary host/microbe metatranscriptomes as an accurate diagnostic indicator of oral cancer
NPJ Genomic Medicine
Read morePartners
Our collective makes us stronger. We couldn't do what we do without great partners. Together, we're making a difference – join our mission.
Our Mission
We founded Viome Life Sciences with one goal in mind: to tackle the epidemic of chronic diseases, cancer, and aging and empower people with the information they need to live a disease-free life.
Learn more about our work at Viome Life Science
FAQs
CancerDetect® Oral & Throat detects the molecular features associated with oral cavity cancer (Oral Squamous Cell Carcinoma or OSCC) and/or throat cancer (oropharyngeal squamous cell carcinoma or OPSCC).
- Sensitivity: 90% for both oral & throat cancer
Sensitivity refers to a test's ability to designate an individual with a disease as positive. A highly sensitive test means that there are few false-negative results, and thus fewer cases of the disease are missed. - Specificity: 95% for both oral & throat cancer
Specificity refers to a test's ability to designate an individual who does not have a disease as negative. A highly specific test means that there are few false-positive results, and thus few false alarms.
A healthcare provider licensed in your state will review your result, and provide a consultation over the phone to discuss the test result, provide educational information, and talk about your next steps. However, no medical advice, treatment, or prescriptions will be provided.
CancerDetect does not detect molecular features associated with other types of cancer other than oral & throat cancers. Please discuss with your doctor about your symptoms and concerns.
- What does a "DETECTED" result mean?
A result of "DETECTED" is not a diagnosis of cancer. The results of the CancerDetect test must be confirmed by diagnostic evaluation suggested by qualified health care professionals in accordance with standard medical practice. These results should be interpreted in the context of the individual's clinical risk factors. Diagnostic decisions are the responsibility of the treating physician. - What does a "NOT DETECTED" result mean?
A result of "NOT DETECTED" does not eliminate the possibility that a cancer is present or will occur in the future. Individuals who receive a "NOT DETECTED" result should continue with all recommended cancer screening options at intervals appropriate for the individual. The use of the CancerDetect test should not replace, supersede, or otherwise alter the use or frequency of standard of care cancer screening or detection modalities. - Do false-positive and false-negative results occur?
False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur.
- What are the requirements to complete this test?
You will need to submit a saliva sample of good quality, create a Viome account, register your test kit and complete the questionnaires in your online account. - What happens if I don't register my test kit?
We will not be able to process your sample if you do not register your test kit. - What happens if I don't complete all required questionnaires?
We will not be able to finalize your test result if you do not complete all required questionnaires.
Work With Us
The mission of the VLS Grants Program is to enable clinicians and scientists worldwide to translate research into commercial products with clinical utility: devising new therapies and developing more accurate diagnostics and companion diagnostics.
Learn moreViome is committed to supporting scientific research by enabling access to data we have included in our publications. We provide access to full summary statistics through a Data Transfer Agreement that protects the privacy of our participant's data.
Request AccessOur team is dedicated to making the advancements in science, technology, and medicine accessible and more readily available to consumers, helping to create a disease free world where people can take control of their own health from the comfort of their own home.
Contact
For partnering opportunities reach out to:
bd@viome.comFor press related inquiries:
press@viome.comFor partnering inquiries regarding Viome consumer tests:
businesspartners@viome.comFor events and speaking inquiries:
events@viome.com